中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2012年
9期
1205-1207
,共3页
王国华%刘辉%袁李礼%吴春苑
王國華%劉輝%袁李禮%吳春苑
왕국화%류휘%원리례%오춘원
酪氨酸/类似物和衍生物/药理学%抽吸%心肌梗死/治疗%血管成形术,经腔,经皮冠状动脉
酪氨痠/類似物和衍生物/藥理學%抽吸%心肌梗死/治療%血管成形術,經腔,經皮冠狀動脈
락안산/유사물화연생물/약이학%추흡%심기경사/치료%혈관성형술,경강,경피관상동맥
Tyrosine/analogs & derivatives/pharmacology%Suction%Myocardial infarction/therapy%Angioplasty,transluminal,percutaneous coronary
目的 观察急性ST段抬高性心肌梗死(ST-EMI)患者行急诊冠状动脉介入治疗(PCI)过程中及术后,DIVERTM CE血栓抽吸导管与血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班(冠状动脉内推注后静脉滴注维持)联合应用的临床疗效及安全性.方法 选择2008年4月至2011年3月间符合PCI治疗条件的急性ST段抬高性心肌梗死患者共60例.按入院顺序将患者随机归为两组:32例(A组)患者给予替罗非班;28例患者(B组)给予DIVERTM CE血栓抽吸导管与替罗非班联合应用.比较两组患者手术前后的心肌梗死血管(TIMI)血流变化、出血性并发症和住院期间主要心脏不良事件( MACE)的发生率.结果 B组术后即刻TIMI血流改善效果明显优于A组,在住院期间MACE的发生率低于A组(25.0% vs 3.6%,P<0.05),两组均无致命性出血并发症.结论 在急性ST段抬高性心肌梗死PCI中应用DIVERTM CE血栓抽吸导管与替罗非班(冠状动脉内推注后静脉滴注维持)能够明显减少冠状动脉内血栓,减少无复流现象,降低住院期间心血管事件发生率,亦无致命性出血并发症,是一种安全有效的治疗方法.
目的 觀察急性ST段抬高性心肌梗死(ST-EMI)患者行急診冠狀動脈介入治療(PCI)過程中及術後,DIVERTM CE血栓抽吸導管與血小闆糖蛋白Ⅱb/Ⅲa受體拮抗劑替囉非班(冠狀動脈內推註後靜脈滴註維持)聯閤應用的臨床療效及安全性.方法 選擇2008年4月至2011年3月間符閤PCI治療條件的急性ST段抬高性心肌梗死患者共60例.按入院順序將患者隨機歸為兩組:32例(A組)患者給予替囉非班;28例患者(B組)給予DIVERTM CE血栓抽吸導管與替囉非班聯閤應用.比較兩組患者手術前後的心肌梗死血管(TIMI)血流變化、齣血性併髮癥和住院期間主要心髒不良事件( MACE)的髮生率.結果 B組術後即刻TIMI血流改善效果明顯優于A組,在住院期間MACE的髮生率低于A組(25.0% vs 3.6%,P<0.05),兩組均無緻命性齣血併髮癥.結論 在急性ST段抬高性心肌梗死PCI中應用DIVERTM CE血栓抽吸導管與替囉非班(冠狀動脈內推註後靜脈滴註維持)能夠明顯減少冠狀動脈內血栓,減少無複流現象,降低住院期間心血管事件髮生率,亦無緻命性齣血併髮癥,是一種安全有效的治療方法.
목적 관찰급성ST단태고성심기경사(ST-EMI)환자행급진관상동맥개입치료(PCI)과정중급술후,DIVERTM CE혈전추흡도관여혈소판당단백Ⅱb/Ⅲa수체길항제체라비반(관상동맥내추주후정맥적주유지)연합응용적림상료효급안전성.방법 선택2008년4월지2011년3월간부합PCI치료조건적급성ST단태고성심기경사환자공60례.안입원순서장환자수궤귀위량조:32례(A조)환자급여체라비반;28례환자(B조)급여DIVERTM CE혈전추흡도관여체라비반연합응용.비교량조환자수술전후적심기경사혈관(TIMI)혈류변화、출혈성병발증화주원기간주요심장불량사건( MACE)적발생솔.결과 B조술후즉각TIMI혈류개선효과명현우우A조,재주원기간MACE적발생솔저우A조(25.0% vs 3.6%,P<0.05),량조균무치명성출혈병발증.결론 재급성ST단태고성심기경사PCI중응용DIVERTM CE혈전추흡도관여체라비반(관상동맥내추주후정맥적주유지)능구명현감소관상동맥내혈전,감소무복류현상,강저주원기간심혈관사건발생솔,역무치명성출혈병발증,시일충안전유효적치료방법.
Objective To assess the effects and safety of glycoprotein Ⅱ b/Ⅲ a receptor inhibitors tirofiban( intracoronary administration and venous maintenance) combined with DIVERTM CE thrombus-aspiration catheter in the percutaneous coronary intervention (PCI)-treated patients with acute ST-segment elevation myocardial infarction (ST-EMI).Methods Sixty patients with ST-EMI who underwent PCI were randomized into two groups.Thirty-two patients in group A were treated with tirofiban,twenty-eight patients in group B were treated with tirofiban and thrombus-aspiration catheter.Between two groups,the thrombolysis in myocardial infarction (TIMI) risk score,hemorrhagic complications,and incidence of major adverse cardiovascular events (MACE) were compared.Results The TIMI flow was improved in both groups,and it was better in group B than group A ( P < 0.05 ).The incidence of MACE in group B was lower than group A (25.0% vs 3.6%,P <0.05). No fatal hemorrhagic complications were found in both groups.Conclusions Application of tirofiban and DIVERTM CE thrombus-aspiration catheter is safe and effective in ST-EMI patients,which can greatly improve myocardial reperfusion and reduce incidence of MACE.